The Federal Funding Programme for COVID-19 Medicines supported innovative pharmaceutical projects that make a contribution to the secure and rapid supply of COVID-19 medicines. The medicines should be available to the Swiss population by the end of 2022.
During its session on 30 June 2021, the Federal Council mandated Innosuisse and us to implement the funding programme jointly. The call for applications started on 19 July and closed on 16 August 2021.
The nine funding applications received, with a total requested funding amount of around CHF 52 million, were evaluated by experts on behalf of Innosuisse and the FOPH.
In late 2021, the federal government signed contracts with four companies based in Switzerland for the development of drugs to treat COVID-19: media release.
In 2022, the projects for the first two medicines mentioned were cancelled due to insufficient effectiveness. The other two projects remain in the funding programme which, according to the Federal Council’s decision of 26 April 2023, will continue until no later than the end of June 2024.
Last modification 22.06.2023
